BLISS GVS PHARMA LTD. - 506197 - Corporate Action-Board approves Dividend
Recommended Final Dividend of 50% i.e. 0.50 paisa per equity share having face value of Rs.1/- each for the financial year ended March 31, 2023, subject to approval of the shareholders in the forthcoming 38th Annual General Meeting of the Company ('38th AGM') BLISS GVS PHARMA LTD. - 506197 - Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2023
We would like to inform you that, the Board Meeting of the Company was held today i.e. Thursday, May 11, 2023 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the matters amongst others as attached. BLISS GVS PHARMA LTD. - 506197 - Board Meeting Intimation for Approving The Standalone And Consolidated Audited Financial Results For The Quarter/Financial Year Ended March 31, 2023 And Recommending Dividend, If Any, On The Equity Shares Of The Company For The Year Ended March 31 2023.
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2023 ,inter alia, to consider and approve a) To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2023, along with the Statement of Assets and Liabilities, Cash Flow Statement and take note of the Audit Report with modified opinion, if any, thereon; b) To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31, 2023; and c) To discuss and recommend the Final Dividend, if any, for the financial year ended March 31, 2023. BLISS GVS PHARMA LTD. - 506197 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyBLISS GVS PHARMA LTD. 2CIN NO.L24230MH1984PLC034771 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 52.05 4Highest Credit Rating during the previous FY IVRBBBSTABLE 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INFOMERICS VALUATION AND RATING PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Aditi Bhatt Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Deepak Sawant Designation: Chief Financial Officer EmailId: [email protected] Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. BLISS GVS PHARMA LTD. - 506197 - Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015 For The Year Ended March 31, 2023
Please find enclosed herewith the yearly compliance certificate issued by the Company Secretary in Practice as per Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2023. Kindly take the same on record. BLISS GVS PHARMA LTD. - 506197 - Compliance Certificate Under Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Period April 01, 2022 To March 31, 2023.
Please find enclosed herewith the compliance certificate under Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the period April 01, 2022 to March 31, 2023. This is for your information and records. BLISS GVS PHARMA LTD. - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2023. BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, we would like to inform you that, Credit Rating of the Company has been reaffirmed by M/s. Infomerics Valuation and Rating Private Limited w.r.t. bank facilities. Enclosed herewith please find the details of the rating for the credit facilities of the Company. BLISS GVS PHARMA LTD. - 506197 - Closure of Trading Window
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited will remain closed for Insiders, Designated Persons and their immediate relatives of the Company with effect from Saturday, April 01, 2023 until 48 hours after the announcement of the Audited Financial results of the Company for the quarter and year ended March 31, 2023. The Board meeting for the declaration of Audited Financial Results for the quarter and year ended March 31, 2023 shall be intimated later. Accordingly, Insiders, Designated Persons, and their immediate relatives are advised not to trade (buy or sell or pledge etc.) in the securities/shares of the Company during the aforesaid period of closure of the Trading Window. BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Registrar and Share Transfer Agent of Company M/s. Universal Capital Securities Private Limited have received a request to issue of duplicate share certificate consequent to loss of share certificate from the shareholder.